251 related articles for article (PubMed ID: 31765786)
21. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
22. Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions.
Dos Santos Matos AP; Lopes DCDXP; Peixoto MLH; da Silva Cardoso V; Vermelho AB; Santos-Oliveira R; Viçosa AL; Holandino C; Ricci-Júnior E
Drug Deliv Transl Res; 2020 Dec; 10(6):1552-1570. PubMed ID: 32676952
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B.
Valdivieso E; Mejías F; Carrillo E; Sánchez C; Moreno J
Int J Antimicrob Agents; 2018 Nov; 52(5):682-687. PubMed ID: 29969693
[TBL] [Abstract][Full Text] [Related]
24. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis.
Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK
Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222
[TBL] [Abstract][Full Text] [Related]
25. Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of
Anjum A; Shabbir K; Din FU; Shafique S; Zaidi SS; Almari AH; Alqahtani T; Maryiam A; Moneeb Khan M; Al Fatease A; Bashir S; Khan GM
Drug Deliv; 2023 Dec; 30(1):2173335. PubMed ID: 36722301
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
[TBL] [Abstract][Full Text] [Related]
27. Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell.
Dar MJ; Din FU; Khan GM
Drug Deliv; 2018 Nov; 25(1):1595-1606. PubMed ID: 30105918
[TBL] [Abstract][Full Text] [Related]
28. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.
Frankenburg S; Glick D; Klaus S; Barenholz Y
Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis.
Pinheiro IM; Carvalho IP; de Carvalho CE; Brito LM; da Silva AB; Conde Júnior AM; de Carvalho FA; Carvalho AL
Exp Parasitol; 2016 May; 164():49-55. PubMed ID: 26902606
[TBL] [Abstract][Full Text] [Related]
30. Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani.
Tripathi P; Jaiswal AK; Dube A; Mishra PR
Int J Biol Macromol; 2017 Dec; 105(Pt 1):625-637. PubMed ID: 28716750
[TBL] [Abstract][Full Text] [Related]
31. Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl.
Hamzavi SS; Sanaei Dashti A; Kadivar MR; Pouladfar G; Pourabbas B
Pediatr Infect Dis J; 2018 Mar; 37(3):275-277. PubMed ID: 29424815
[TBL] [Abstract][Full Text] [Related]
32. Development of antileishmanial lipid nanocomplexes.
Pham TT; Gueutin C; Cheron M; Abreu S; Chaminade P; Loiseau PM; Barratt G
Biochimie; 2014 Dec; 107 Pt A():143-53. PubMed ID: 24952352
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607026
[TBL] [Abstract][Full Text] [Related]
35. Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes.
Nazari-Vanani R; Vais RD; Sharifi F; Sattarahmady N; Karimian K; Motazedian MH; Heli H
Acta Trop; 2018 Sep; 185():69-76. PubMed ID: 29733808
[TBL] [Abstract][Full Text] [Related]
36. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
[TBL] [Abstract][Full Text] [Related]
37. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
38. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
[TBL] [Abstract][Full Text] [Related]
39. Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis.
Caldeira LR; Fernandes FR; Costa DF; Frézard F; Afonso LC; Ferreira LA
Eur J Pharm Sci; 2015 Apr; 70():125-31. PubMed ID: 25660615
[TBL] [Abstract][Full Text] [Related]
40. Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis.
Khan AS; Ud Din F; Ali Z; Bibi M; Zahid F; Zeb A; Mujeeb-Ur-Rehman ; Khan GM
Int J Pharm; 2021 Jan; 593():120109. PubMed ID: 33253802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
